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ABSTRACT
Allosteric sites on proteins are targeted for designing more selective inhibitors of enzyme activity and to
discover new functions. Acetylcholinesterase (AChE), which is most widely known for the hydrolysis of the
neurotransmitter acetylcholine, has a peripheral allosteric subsite responsible for amyloidosis in Alzheimer’s
disease through interaction with amyloid b-peptide. However, AChE plays other non-hydrolytic functions.
Here, we identify and characterise using computational tools two new allosteric sites in AChE, which have
allowed us to identify allosteric inhibitors by virtual screening guided by structure-based and fragment
hotspot strategies. The identified compounds were also screened for in vitro inhibition of AChE and three
were observed to be active. Further experimental (kinetic) and computational (molecular dynamics) studies
have been performed to verify the allosteric activity. These new compounds may be valuable pharmaco-
logical tools in the study of non-cholinergic functions of AChE.
ARTICLE HISTORY
Received 8 February 2018
Revised 9 April 2018
Accepted 9 May 2018
KEYWORDS
AChE; allosteric sites;
Alzheimer diseases;
molecular dynamics;
allosteric inhibitors
Introduction
Acetylcholinesterase (AChE) is a well-known enzyme for the
hydrolysis of the neurotransmitter acetylcholine (ACh)1–4, being
the target of the main marketed pharmacological treatment of
Alzheimer’s disease (AD). However, during the past decade it has
been shown that AChE also plays other non-hydrolytic functions.
Several in vitro and in vivo studies in the central nervous system
suggested that developmental regulation of AChE enzyme plays a
role in non-cholinergic function as morphometric processes, cell
differentiation and synaptogenesis along nervous system5. It is
well recognised that one of the non-cholinergic actions of AChE is
neurite promotion, which is regulated by a dynamic equilibrium of
different interactions sites of AChE6,7. Zeev-Ben-Mordehai et al.
published that one of the non-classical roles of AChE might be as
an adhesion protein involved in synaptic development and main-
tenance8. Thus, pharmacological inhibitors of AChE that block the
catalytic activity of the enzyme do not necessarily interfere with
other biological activities of the protein. On the contrary, since
damaging effects of overexpressed AChE may be related to non-
catalytic activities, these drugs may actually aggravate certain con-
ditions by elevating the levels of catalytically inactivated AChE.
To date it is well known that the active site of AChE is subdi-
vided into several subsites: catalytic triad (CAS, Ser-Glu-His) at the
base of the gorge, anionic subsite (AS), acyl-binding pocket, and
peripheral anionic subsite (PAS) at the mouth of the site, being
PAS an allosteric site9. Modulators binding PAS limit the catalytic
efficiency by both ways, combining steric and electrostatic block-
age of ligand trafficking through the gorge and changing the
active site conformation. Several evidences suggest that the
PAS, besides its role in allosteric regulation of AChE-catalysed
hydrolysis, also mediates heterologous protein associations
that contribute to cell recognition and adhesion processes
during synaptogenesis, and to the nucleation of amyloid peptides
during the onset of AD in humans and mammalian
model systems10.
Recently, Marcelo et al. suggested another possible binding
site, called site B, located outside the catalytic gorge. They showed
that rosmarinic acid was able to bind this site; however, its allo-
steric functioning is not clear11.
The “exit doors” are another very interesting structural motif in
the hydrolysis mechanism of AChE. These regions are alternative
routes to the gorge for product clearance, contributing to the
high catalytic activity of the AChE. Computational studies together
with X-ray crystallography suggest three possible regions of AChE
implicated in the removal of cleavage products of the hydrolysis
of ACh, known as back door (including Trp86, Gly448, Tyr449, and
Ile451 (hAChE residue numbering)). Side door (including Asp74,
Thr75, Leu76, Thr83, Glu84, and Asn87) and acyl loop door (includ-
ing Trp236, Arg247, and Phe297)12–15.
There are many challenges that need to be addressed regard-
ing the non-classical functions of AChE, such as to identify the
allosteric sites, the amino-acid residues that mediate non-classical
activities and the identification of allosteric inhibitors among
others16. Taking into account the relevance of this target in
neurodegenerative diseases we consider that it is of great import-
ance to identify allosteric sites as starting point to develop
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efficient modulators of AChE and the corresponding non-
cholinergic functions.
The main goal of this work is the identification and description
of new allosteric binding sites on AChE and the discovery of new
allosteric inhibitors since allosterism represents one of the most
common and powerful means to regulate protein function. For
this purpose, we performed a search for druggable sites on the
enzyme using computational approaches with the aim of identify-
ing putative allosteric sites. Moreover, for each of these we have
defined the interacting key residues by means of virtual screening
of our Medicinal and Biological Chemistry (MBC) library17, and a
plausible mechanism of action is proposed.
Methods
Computational studies
Pocket search
In order to identify different cavities on the AChE enzyme, the
Fpocket software18, a highly scalable and open source pocket-
detection software package, was used. Fpocket is freely available
for download at http://www.sourceforge.net/projects/fpocket.
Fpocket extracts the information from rigid structure and only it is
based on geometric parameters. Fpocket is based on the concept
of a a-sphere, which is defined as a sphere that contacts four
atoms on its boundary and has no internal atom. For a protein,
very small spheres are located inside the protein, large spheres at
the exterior, and clefts and cavities correspond to spheres of inter-
mediate radii19.
The use of Fpocket software involves three major steps. During
the first step, the whole ensemble of a-spheres is determined
from the protein structure and a pre-filtered collection of spheres
is returned. The second step consists of identifying clusters of
spheres close together, identifying pockets, and removing no
interesting clusters. The final step is the atom properties calcula-
tion from each pocket, in order to score and rank the identi-
fied pockets.
Fourteen hAChE structures (PDB IDs: 1B41, 1F8U, 2X8B, 3LII,
4BDT, 4EY4, 4EY5, 4EY6, 4EY7, 4EY8, 4M0E, 4M0F, 4PQE, 5FPQ)20–27
were downloaded from the Protein Data Bank (www.pdb.org) and
subjected to pocket search using Fpocket. The PDB structures
were prepared using the Maestro28 Protein Preparation Wizard29
for removing the water molecules, ligands, and metal ions. Upon
Fpocket search, the 14 structures with embedded centres of
pocket a-spheres were analysed by visual inspection to identify
conserved pockets.
Hotspot analysis
The Fragment Hotspot maps software30 identifies the location and
quality of binding sites on the protein by first calculating atomic
hotspots and then producing Fragment Hotspot maps with simple
molecular probes. These maps specifically highlight fragment-bind-
ing sites and their corresponding pharmacophores. H-Bond
acceptor, donor, and apolar/aromatic interactions, reported by
this software, can assist medicinal chemists search for interesting
interactions in order to bind or improve the binding affinities for
different ligands, and suggest modifications to the molecules. For
the molecular modeller, the maps complement existing virtual
screening methods because they can be visually inspected to gen-
erate docking constraints or structure-based pharmacophores.
With the most important interactions highlighted, existing
pharmacophore methods can be used to screen for molecules
capable of making these essential interactions. The maps can also
be used to generate constraints for docking and hence steer the
docking towards occupying the hotspot and ensuring that the
important potential interactions are satisfied.
Structure preparation of hAChE in its apo state (PDB ID: 4EY4)
for the hotspot calculation was performed using Protein
Preparation Wizard29, implemented in Maestro28. Ligands and
water molecules were removed, hydrogen atoms were added and
protein residues were ionised at pH¼ 7. After the target prepar-
ation, Fragment Hotspot maps were calculated using the in-house
script developed by Chris Radoux in Cambridge. The Hotspot
Maps30 were visualised using PyMol31 software in order to identify
the residues which could be involved in the interaction between
ligand and protein.
Ligand preparation
The preparation of the library and the 2D-to-3D conversion was
performed using the LigPrep32 tool, a module of the Schr€odinger
software package. LigPrep allows different preparation steps of
molecules such as the addition of hydrogen atoms, neutralisation
of charged groups, generation of ionisation states, low-energy ring
conformations, possible tautomers, followed by energy minimisa-
tion using the OPLS-2005 force field33,34. In order to carry out our
studies, the compounds were prepared at physiological pH condi-
tions, all of the compounds were desalted and finally the com-
pounds were minimised as default. A total of 2499 protonation
and tautomeric states were generated from 1830 compounds of
MBC library using LigPrep.
Virtual screening
Virtual Screening of the MBC library17 was carried out using the
Glide software35, with the Extra Precision (XP) Glide Mode, for the
site 2 and site 3 of the 4EY4 structure which was previously pre-
pared using Protein Preparation Wizard tool. This structure was
selected because of its being the only apo form amongst the serie
of AChE crystallographic structures22; it also has a very good reso-
lution and excellent validation values, such as few Ramachandran
outliers. The small-molecule-bound docked poses were further
filtered using Maestro Pose Filter, selecting only the compounds
that interact through an H-bond with the residues that are known
to be critical for the ligand-target affinity in the Hotspots Maps.
For site 2, the grid was centred on the site 2, ensuring that the
entire cavity was included inside the box, and the molecules were
ranked based on the Glide XP score. The scores for the molecules
were in the range from 8.9 to 4.4 kcal/mol while rosmarinic acid
was ranked with a score of 8.5 kcal/mol. His405, Glu414, and
Trp532 were selected as key residues and applied as inter-
action filter.
For site 3, a Glide XP docking was performed ensuring the
entire cavity was included in the grid. The docking score for the
molecules ranges from 7.7 to 1.8 kcal/mol. Glu81, Glu452, and
Arg463 were selected as key residues for the interaction filtering.
Ligands that are able to interact with these residues were ranked
by their XP Glide Score, and visual inspection of the fitting
between the Hotspot Maps and the best ranked virtual screening
results was used to select molecules for further studies.
Molecular dynamics
Molecular dynamics (MD) was performed on an Asus 1151 h170
LVX-GTX-980Ti workstation, with an Intel Core i7–6500 K Processor
(12M Cache, 3.40 GHz) and 16GB DDR4 2133MHz RAM. The work-
station has Nvidia GeForce GTX 980Ti available for GPU
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computations. MD studies were performed using AMBER1436 with
the ff14SB37 to assess the stability of the compounds and to look
for the ligand’s inhibitory mechanism. Additionally, a MD trajectory
for the apo-target was developed, in order to observe the behav-
iour of the apo-AChE enzyme and to compare it with the ligand-
target trajectories. To calculate the ligands parameters for the MD
simulation, RESP charges were calculated using Gaussian0938, opti-
mising the geometry for both compounds using the method
HF6–31þþ(d,p). Once the optimisation was completed, ligands
were parametrised using Antechamber module39. Systems were
solvated using TIP3P model40 for water molecules, with a cubic
box, equilibrating the system charge by adding Naþ ions. Solvated
systems were first minimised for 8000 steps with the initial 4500
steps using the steepest descent algorithm. The final 3500 steps
used the conjugate gradient energy minimisation with constraints
applied to the protein residues as mentioned above for sites 2 and
3. This was followed by two minimisation stages of 8000 steps
each, with the last 3500 using the conjugate gradient decreasing
the restrains to the system. The system was equilibrated to 300 K
and 1 atm, using a step protocol, applying energetic restraints of
15 kcalmol1Å1 from the initial step and gradually decreasing
them until its disappearing. Trajectories of 25 ns were obtained in
isothermal–isobaric ensembles. All bonds involving hydrogen
atoms were constrained with the SHAKE algorithm41. A cut-off of
10Å was used for the Lennard–Jones interaction and the short-
range electrostatic interactions. Berendsen barostat42 and
Langevin thermostat were used to regulate the system pressure
and temperature, respectively. Trajectories of 25 ns were com-
puted, analysed using the Cpptraj43 module and VMD44 for visual
inspection. Xmgrace software45 was used to obtain the graphics of
root-mean-square deviation (RMSD) and root-mean-square fluctu-
ation (RMSF) of the MD simulations.
One of each five frames of the trajectories were saved into a
new PDB format trajectory and were taken to further analysis
using TRAnsient Pockets in Proteins (TRAPP) software46, which
allows the simulation, analysis, and visualisation of protein cavity
dynamics for detection of transient sub-pockets using protein
motion trajectories or ensembles of protein structures obtained
either from experiments or from simulations. The catalytic pocket
was also analysed using this software.
Biological studies
In vitro cholinesterase inhibition assays
The method was adapted from Ellman et al.47 The assay solution
consisted of 0.1M phosphate buffer pH 8, 400mM 5,50-dithiobis(2-
nitrobenzoic acid) (DTNB, Ellman’s reagent), 0.05 unit/ml AChE
(Sigma Chemical Co., Madrid, Spain, Cholinesterase, acetyl human
recombinant), and 800mM acetylthiocholine iodide as the sub-
strate of the enzymatic reaction. The compounds tested were
added to the assay solution and the absorbance changes at
412 nm were recorded for 5min with a UV/Vis Microplate and
cuvette Spectrophotometer, Thermo Electron Type, Multiskan
Spectrum. The reaction rates were compared, and the per cent
inhibition due to the presence of test compounds was calculated.
The IC50 is defined as the concentration of each compound that
reduces the enzymatic activity 50% with respect to that without
inhibitors. All the experiments were performed in triplicate.
Kinetic study of AChE inhibition
To investigate the mechanism of action of the compounds on
AChE, a kinetic analysis was performed. The experiments were
carried out using combinations of four substrate concentrations,
and three inhibitor concentrations. Double-reciprocal
Lineweaver–Burk plotting of the data obtained, in which each
point is mean of three different experiments, were analysed.
Competitive inhibitors have the same y-intercept as uninhibited
enzyme (since Vmax is unaffected by competitive inhibitors the
inverse of Vmax also does not change) but there are different
slopes and x-intercepts. Non-competitive inhibition produces plots
with the same x-intercept as uninhibited enzyme (Km is
unaffected) but different slopes and y-intercepts. Non-competitive
inhibition causes different intercepts on both the y- and x-axes
but the same slope. Mixed inhibitors cause intersects above or
below the x-axis.
Results and discussion
Druggable site
The determination of druggable cavities in therapeutic targets is
essential for structure-based drug design in order to identify bind-
ing pockets or allosteric sites and to design small-molecule ligands
that bind to these with therapeutic effects. To address this goal,
several computational approaches have been developed based
mainly on evolutionary or structure-based algorithms48–51.
In this work, we have used a combination of methods to get a
consensus prediction of protein druggable sites. We have used the
free geometry-based algorithm Fpocket18,19 (http://fpocket.source
forge.net) together with the prediction of Fragment Hotspot
maps30 to study the AChE surface with the aim to identify allo-
steric sites and its key residues.
The first step of this consensus protocol was performed using
the Fpocket software. As Fpocket is a geometry-based pocket-
detection algorithm, we performed the study using a representa-
tive set of hAChE, in both apo and different complexed forms
(Table 1). Fourteen different human structures were available at
the moment of the study in the Protein Data Bank (PDB) (see
Material and Methods section). The software detected almost 30
cavities, with some of these appearing in all AChE structures ana-
lysed, and others, which are not conserved, in fewer crys-
tal structures.
Once all cavities were analysed and clustered, taking into
account the frequency that they appear together, and the drugg-
ability prediction score given by Fpocket, only four highly reprodu-
cible cavities can be considered as putative druggable binding
sites (Figure 1). We observed that the four sites appear in all of
Table 1. Druggable binding sites.
PDB code LIGAND SITE 1 SITE 2 SITE 3 SITE 4
1B41 Fasciculin-II 1 4, 9 2 3
1F8U Fasciculin-II 1 4, 7 3 2
2X8B Fasciculin-II 1 9, 11 6 2
3LII – 1 8, 17 2 7
4BDT Fasciculin-II 1 4, 10 2 5
4EY4 – 2 5, 7 1 4
4EY5 Huperzine 1 4, 6 2 3
4EY6 Galantamine 1 2, 4 3 5
4EY7 Donepezil 1 4, 6 2 3
4EY8 Fasciculin-II 1 6, 10 2 3
4M0E Dihydrotanshinone-I 1 4, 7 2 6
4M0F Territrem B 1 4, 5 2 3
4PQE – 1 2, 3 5, 13 4
5FPQ Sarin 1 3, 5 2 4
The numbers refer to the score given by the program Fpocket to the site in
each structure (the lower score is related to better binding sites). Two or more
numbers indicate that this pocket was found as two different cavities on
the structure.
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the different structures, although the position of each site varies
among the structures and, in the case of site 2, Fpocket detected
it as two different cavities (Table 1).
The best ranked site for all structures is the site 1 (except for
4EY4, for which is the second-best cavity) that corresponds to the
well-known binding site CAS/PAS. The site 2 is ranked at the top
five positions in 11 out of the 14 structures analysed. Inspection of
the residues of this site (Table 2) allowed us to identify Arg296
and Glu369 as possible key binding residues of the rosmarinic acid
as was previously described by Marcelo et al.11 Some residues are
also shared with the acyl loop door14 such as Trp236, Arg247, and
Phe297 (Figure 2).
The site 3, in 13 out of the 14 structures analysed, is ranked in
the top five positions. We identified residues Val132, Tyr449, and
Glu452 as residues (Table 2) that take part of the so-called back
door, described as a dimple on the surface of the protein52.
The remaining site 4 corresponds to a cavity formed mostly by
polar residues such as Asp333, Glu334, His381, Glu396, and
Asp400. Since no molecular or biological function can be attrib-
uted to these residues, we did not pursue the study of this cavity.
However, the possibility of using site 4 for the design of new allo-
steric modulators of AChE remains open for future work. The
known side door53,54 was also detected by Fpocket, although this
cavity was not found in most of the structures (see Supporting
Information).
Volume characterisation
Further we noticed that there was a fluctuation in the volume of
the site 2 and site 3 when a ligand is bound in catalytic gorge. To
analyse these fluctuations we use Fpocket to compare a series of
structures crystallised in the same conditions (4EY4, 4EY5, 4EY6,
4EY7, 4EY8). We observed that the site 2 decreases its volume
when a ligand is bound to the catalytic gorge except to complex
4EY6 (Figure 3). These changes in the volume present a logical
issue, because site 2 and CAS have some common residues, so
ligands in the active gorge can interact and displace these resi-
dues as a consequence and hence modify the contiguous cavity.
Similar changes might affect the active gorge when a ligand binds
the site 2, explaining a possible allosteric mechanism. Moreover, it
has been reported that the structural perturbations of the acyl
loop occur when AChE is inhibited by a covalent inhibitor, pre-
senting a narrowing of the gorge and a displacement of the
Arg296 into the active site, which could present a steric barrier to
the entry of oximes or affect oxime binding for AChE reactiva-
tion55. In our case, the hypothesis that a ligand binds to site 2 and
displaces the acyl loop, thus inhibiting AChE activity, will be fur-
ther studied.
We next studied the influence of the ligand in complexes 4EY7
(with donepezil) and 4EY8 (with fasciculin-2) on the volume of the
site 3. Interestingly, we found that in both cases the site 3 rises its
volume approximately by two-fold as compared to the apo struc-
ture. This could be explained by the opening of the back door in
both complexes, while the others remain closed.
Figure 1. AChE structure highlighting the best cavities found by Fpocket.
Table 2. Residues of allosteric sites, site 2 and site 3.
Allosteric site Residues
Site 2 Pro232, Asn233, Gly234, Pro235, Trp236, Thr238, Val239,
Gly240, Glu243, Arg246, Arg247, Leu289, Por290, Gln291,
Ser293, Arg296, Phe297, Val300, Thr311, Pro312, Glu313,
Pro368, Gln369, Val370, Asp404, His405, Cys409, Pro410,
Gln413, Trp532, Asn533, Leu536, Pro537, Leu540
Site 3 Glu81, Gly82, Glu84, Met85, Asn87, Asn89, Leu130, Asp131,
Val132, Thr436, Leu437, Ser438, Trp439, Tyr449, Glu452,
Ile457, Ser462, Arg463, Asn464 y Tyr465
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These results, indicative of a volume fluctuation of allosteric
sites, get with Fpocket are preliminary but suggesting an interrela-
tion between catalytic site and allosteric ones.
Key residues
In order to confirm the druggability of the allosteric sites and to
identify its key residues, we next performed a theoretical study of
potential fragment-binding sites using Fragment Hotspot maps30
for each site detected by Fpocket. These hotspot maps provide vis-
ual guides of the fragment-binding sites and their corresponding
pharmacophores. This method reports H-Bond acceptor, donor, and
non-polar/aromatic interactions, helping in the search for interest-
ing interactions in order to identify or design efficient inhibitors.
Figure 4 shows the Fragment Hotspot maps of the AChE apo
structure (PDB ID 4EY4). The analysis of the hotspot was focussed
on sites 2 and 3. We found that key residues Gln413 and Trp532 in
site 2 can act as acceptors and His405 as H-Bond donor. These
interactions represent the theoretical minimum binding features
that will allow a fragment to bind this cavity.
Fragment Hotspot maps for the site 3 were also analysed, dem-
onstrating that the key residues are Glu81 and Glu452 as accept-
ors and Arg463 as a H-Bond donor.
In summary, considering all above results we can conclude that
druggable sites (sites 2 and 3) could be possible allosteric sites and
targeting them might lead to the modification of AChE activity.
Virtual screening
With the goal of searching for allosteric modulators of the sites 2
and 3, we performed a virtual screening using our in-house MBC
chemical library17. To validate the computational screening, dock-
ing of donepezil and rosmarinic acid for both sites (CAS/PAS and
site 2) was also performed using Glide software (see Supporting
Information, Figures S1 and S2). Upon validation, a virtual screen-
ing was performed using Glide with XP for both sites.
Site 2 virtual screening
Eleven compounds were chosen for enzymatic assay. Two of these
compounds were selected based on their docking score. The rest of
them were selected by an interaction-filter based on the Fragment
Hotspot maps that were previously calculated. In this way, a filter of
the capability of the ligands to interact through H-bond with Gln413,
Trp532, and His405 was set up and the results were visually inspected.
Along with the 11 compounds selected, rosmarinic acid was also sent
for biological evaluation on AChE as a control11 (Table 3).
All the compounds tested showed a percentage of AChE inhib-
ition at 10 lM greater than rosmarinic acid (the control compound
in the assay), consistent with the proposed common binding site
in the enzyme. Very interesting is the case of pteridine derivative
SC251 with an IC50 value of 2.7 lM.
Figure 5 displays a three-dimensional view of the predicted
binding pose of SC251 at site 2. SC251 interacts by a donor hydro-
gen bond with Gln413, an acceptor H-bond with His405 and a
donor H-bond with Asn533, fitting properly with the Fragment
Hotspot maps results.
To confirm a possible allosteric mechanism of inhibition, we
perform competitive studies of SC251 with the natural substrate,
acetylcholine (ACh) (Figure 6). A non-competitive-mixed
Figure 2. Amino acids involved in site 2 and site 3 found in hAChE (PDB ID: 4EY4). Site 2 residues are shown in orange and site 3 residues are shown in blue.
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mechanism was observed suggesting that SC251 should bind to
an allosteric site, in addition to the catalytic site.
MD
With the aim of explaining a plausible mechanism of action for
the allosteric inhibitor SC251, MD studies for AChE in the apo state
and AChE-SC251 complex were carried out. MD studies provide a
powerful method to follow intimate details of the conformational
events in different biological systems. In this study, flexibility
changes or behaviour modifications in the important sites of AChE
upon inhibitor binding, at the sites 2 and 3, and the side door cav-
ity were further analysed.
To explore the dynamic stability of the trajectories, RMSD val-
ues of the protein backbone based on the starting structure along
the simulation time were calculated and plotted (Figure S4). After
the initial adjustment, the longer term RMSD values are stable,
ranging from 1.0 to 1.9 Å during the entire simulation time.
Figure 3. (A) Surface representation of pockets that belong to site 2 (orange) and site 3 (blue). Differences between the volume in the absence and presence in the
CAS/PAS cavity of inhibitor are highlighted (4EY4 is AChE in the apo state, 4EY7 is AChE crystallised with donepezil). (B) Plots of volume measured in some structures
crystallised in the same conditions for site 2 (orange) and site 3 (blue).
Figure 4. Representation of the calculated hotspots using Fragment Hotspot maps software30. Yellow area refers to non-polar area where the ligand should make
hydrophobic interactions. Blue dots represent the area where the ligand should make a donor H-bond, and red dots where acceptor H-bond should be formed.
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Table 3. Experimental inhibition values of the virtual screening compounds to bind site 2.
Compounds Structure IC50 (lM)
a Interactions (H-bonds)
VSP2.47 >10 (35%) Asn233, His405
DA003 >10 (40%) His405, Trp532
SC274 >10 (33%) Asn233, Asn533, Trp532
AEL039 >10 (45%) Asn233, His405, Trp532
SC653 >10 (26%) Trp532, Asn233
JHD1.21 >10 (33%) Asn533, His405
MR3.61 >10 (37%) Asn233, Asn533, His405
AEL011 >10 (44%) Asn533, His405
SC251 2.76 ± 0.25b Gln413, Asn533, His405
VP2.42 >10 (39%) Trp532
SC008 >10 (38%) His405, Trp532
Rosmarinic acid >10 (26%) Asn533, Gln413, Thr238, Pro368, Arg296
Key interactions of the compounds with AChE are display.
a% of inhibition at 10 lM is indicated into parentheses.
bIC50 curve of compound SC251 (see supporting information, Figure S3).
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Along the trajectory, the ligand SC251 fluctuates around the
predicted docking poses (Figure S5). Accordingly, during the simu-
lation, the ligand maintains some of the strong interaction as the
H-bond donor with the Asn533 (during the 85% of the simulation)
and the H-bond acceptor with the His405 (during the 50% of the
simulation). However, the H-bond donor with Gln413 is lost in the
majority of the simulation, and appears only 2% of the simulation
time as it can be observed in Figure S6 (in order to clarify the final
bind mode of the complex, a picture is shown in Figure S7).
The RMSF of the apo and bound state were compared in order
to see any differences in the fluctuations of the residues (Figure
S8). The most interesting change corresponds to the residues
70–78, that belong to the omega loop, that are also implicated in
the side door. We can identify rigidity of these residues when
SC251 binds the site 2, as demonstrated by the decrease in fluctu-
ations from approximately 3 Å to barely 1 Å, which might suggest
the impossibility of opening the side door while the ligand remains
bound to the site 2.
To further analyse the conformational changes between the
trajectories, we used TRAPP software46. TRAPP is a tool that allows
the analysis of the evolution of the spatial and physicochemical
properties of a specified pocket in a protein during a MD simula-
tion. We selected one out of five frames of the simulation as an
input for TRAPP. We first analysed the CAS/PAS cavity of the apo
AChE trajectory, which reveals that our molecular dynamic study
also shows the presence of the side and back doors in at least the
50% of the trajectory, as other previous studies have already pub-
lished56 (Figure 7(A)). The acyl loop door is less flexible therefore
the gate opening is more difficult to occur, as other studies have
also previously reported56, thus we only can see its opening in
25% of the total snapshots of the simulation.
Analysing the CAS/PAS cavity of the complex AChE-SC251 tra-
jectory, some interesting differences with the apo form are high-
lighted. As we commented above, while the omega loop of the
apo state of AChE is very flexible and allows the opening of the
side door, in the AChE-SC251 trajectory this loop is much more
rigid and as a result, the side door opens only in <50% of the
snapshots of the trajectory. A red area appears in the back door
Figure 5. Superposition of the proposed pose for SC251 at Site 2 and the hotspot
calculated with Fragment Hotspot maps software.
Figure. 6. Lineweaver–Burk plots representing the reciprocal of initial enzyme velocity versus the reciprocal of ACh concentration in the absence and presence of
different concentrations of SC251 (1–5lM). Each point is the mean of three different experiments.
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region of the apo AChE trajectory, indicating a transient pocket
when the back door is opening (Figure 7). However, for the AChE-
SC251 trajectory we can see instead a big disappearing area (in
blue, Figure 7), suggesting the impossibility for this door to open.
Another difference is also noticed near the acyl loop, while the
loop remains rigid in the apo trajectory, for the AChE-SC251 trajec-
tory a disappearing area is situated near it, suggesting a slight dis-
placement of these residues into the CAS/PAS cavity.
In general terms, we observe a stiffness of the doors. All of these
data are in agreement with the allosteric theory that proposes that
the binding of a ligand can reduce the entropy of the system in
such a way that the conformation of the protein is fixed, restricting
its movement and thus modifying the target behaviour57.
Site 3 virtual screening
For the site 3, no ligands can be used as a control for docking cal-
culations since no previous studies have been carried out. Thus,
the same docking conditions as for the virtual screening in the
site 2 were used, following Fragment Hotspot maps leads.
In this case, 14 compounds were selected for biological evalu-
ation using the hotspots calculated as a filter for the screening.
Four different filters were set, taking into account the ability of
the ligands to make an H-bond interaction with Arg463, Glu452,
and Glu81.
As given in Table 4, two compounds, VP2.33 and SC035,
showed an IC50 of 50 lM. A competition study for both was per-
formed showing a non-competitive inhibition. At larger concentra-
tions of substrate, the inhibition percentage slightly decreases, as
shown in graphic of Figure 8.
Clearly, both compounds bind to AChE at an allosteric site. To
further validate the allosteric behaviour of these compounds we
measured their inhibitory capacity in the presence of the pure
competitive inhibitor JTE-90758. If our hypothesis is right, the bind-
ing of VP2.33 and SC035 to the allosteric site 3 in presence of JTE-
907 should show a cooperative behaviour in terms of inhibition of
the AChE.
Table 5 shows the inhibitory value of each compound and their
sum. In the case of VP2.33 the data indicate an effect of coopera-
tive activities. These data support a model where both compounds
collaboratively participate in the inhibition of AChE by targeting
different sites in the enzyme.
However, when the experiment was performed with SC035,
there is no addition of activities (Table S1) and therefore the
results are not conclusive for this compound.
Since the interactions of SC035 and VP2.33 are different
(Figure 9), both compounds could be inhibiting the enzymatic
Figure 7. (A) TRAPP analysis for the apo AChE trajectory. (B) TRAPP analysis for the AChE-SC251 trajectory. Blue areas represent disappearing areas at the 50% of the
snapshots, red areas represent appearing areas at the 50% of the snapshots. Green loop corresponds to the side door, orange loop to the acyl-loop and the blue resi-
dues to the back door.
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Table 4. Experimental inhibition value of the identified compounds to bind site 3 and binding interactions with AChE.
Compound Structure IC50 (lM)
a Interactions (H-bonds)
SC867 >50 Arg463, Tyr465
AC088 >50 Glu81
SC507 >50 (24%) Glu452
SC872 >50 Glu452, Arg463
SC003 >50 Glu452, Arg463
SC319 >50 Glu81, Glu452, Arg463
AEL040 >50 Glu81, Ser438
AC051 >50 Glu81
SC484 >50 Glu81
VP2.33 49.6 ± 1.5b Glu81
VNG1.9 >50 Glu81, Asn464
SC035 42.1 ± 4.3b Arg463, Tyr465
SC045 >50 Glu452, Arg463, Tyr465
VP1.58 >50 Glu81, Glu452, Thr436
a% of inhibition at 50 lM is indicated into parentheses.
bIC50 curve of compounds VP2.33 and SC035 (see supporting information, Figures S9 and S10).
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activity but with different mechanisms of action, explaining the
difference when the sum of activities is measured.
Molecular dynamics
Further MD studies have been carried out to study the behaviour
of the complex AChE-VP2.33 in order to propose a possible mech-
anism of action of this compound.
The RMSD values of the protein backbone based on the start-
ing structure along the simulation time were calculated and plot-
ted (Figure S11). After the initial adjustment, the longer term
RMSD values are stable, ranging from 1.2 to 1.8 Å during the entire
simulation process.
Along the simulation of the AChE-VP2.33 complex, we found
that the compound pose remains stable along the trajectory
(Figure S12), maintaining the H-bond donor interactions with the
Figure 8. Lineweaver–Burk plots representing the reciprocal of initial enzyme velocity versus the reciprocal of ACh concentration in the absence and presence of
different concentrations of VP2.33 and SC035. Each point is the mean of three different experiments.
Table 5. Results of the inhibition of AChE with JTE-907 and VP2.33.
VP2.33 50 lM VP2.33 25 lM
(57.71 ± 1.38%) (27.28 ± 3.51%)
JTE907 20 lM (65.10 ± 2.37%) 90.06 ± 1.05 80.76 ± 1.15
DIJTE907¼ 24.96 DIJTE907¼ 15.66
DIVP2.33¼ 32.35 DIVP2.33¼ 53.48
JTE907 10 lM (56.78 ± 1.35%) 85.42 ± 1.74 68.57 ± 1.91
DIJTE907¼ 28.74 DIJTE907¼ 11.79
DIVP2.33¼ 27.71 DIVP2.33¼ 41.29
JTE907 5lM (30.34 ± 2.85%) 74.87 ± 2.01 50.20 ± 2.73
DIJTE907¼ 44.53 DIJTE907¼ 19.86
DIVP2.33¼ 17.16 DIVP2.33¼ 22.90
The value in parentheses corresponds to individual inhibition of each compound.
Figure 9. Superimposition of the proposed pose for VP2.33 (blue) (A) and SC035 (orange) (B) at Site 3 and the hotspot calculated with Fragment Hotspot
maps software.
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Glu452 (during the 95% of the simulation) and H-bond donor and
acceptor interactions with the Thr436 (during 30% of the simula-
tion) (Figures S13–S14).
The RMSF of the apo and bound forms were computed and
compared in order to see any differences in the fluctuations of the
residues (Figure S15). One of the differences lie on the omega
loop residues, in which a decrease in the loop flexibility occurs
when VP2.33 binds the site 3. Other two regions that also lose
flexibility are residues 251–260 and residues 330–347 that com-
prise loops exposed to the solvent. This rigidity process, when
VP2.33 binds AChE, suggests the stabilisation of the complex,
reducing its Gibbs free energy and entropy values59.
To verify these changes, we studied different areas of AChE
along the MD trajectory using TRAPP software. The normal behav-
iour of the omega loop that corresponds to the opening of the
side door is modified when the ligand is bound to the target. In
the apo form a red area appears (new transient pocket) pointing
out the opening of the side door, meanwhile this new transient
pocket does not appear in the complex AChE-VP2.33 (Figure 10).
This fact could suggest that compound VP2.33 could be able to
modify the behaviour of the omega loop residues, as shown in
the RMSF data in Figure S4.
Regarding the back door, significant differences are not appreci-
ated in the movement of the residues involved in the opening of
this door between the two trajectories. This suggests that the com-
pound VP2.33 might block the clearance of ACh, without modifying
the movement of the residues involved in the back door.
In summary, we do not find any significative changes in acyl
loop neither back door. Therefore, we can suggest an innovative
allosteric mechanism of VP2.33 due to the prevention of side door
opening. The residues of this alternative channel present less
movement when VP2.33 is bound to site 3 than the apo trajectory
correlating with a lower efficiency of the clearance of the degrad-
ation products of ACh.
Conclusions
Our main goal in this work was to extend knowledge of the drug-
gable sites of AChE. Since allosterism represents one of the most
common and powerful means to regulate protein function, we
aimed to study the AChE surface to identify allosteric sites. A com-
bination of the free geometry-based algorithm Fpocket with the
Fragment Hotspot maps have allowed the identification of new
allosteric binding sites (sites 2 and 3). We carried out a virtual
screening study of our in-house library to identify allosteric inhibi-
tors of sites 2 and 3. We validated the predicted hits with experi-
mental studies (in vitro and kinetic studies). These studies have
culminated with the identification of allosteric compounds. SC251
has been identified as an allosteric inhibitor of site 2 showing a
non-competitive-mixed inhibition. Further MD allowed us to pro-
pose a possible action mechanism of this compound. In relation
to site 3, VP2.33 and SC035 have been identified. Both compounds
show a non-competitive inhibition. Further experimental studies
Figure 10. (A) TRAPP analysis for the apo AChE trajectory. (B) TRAPP analysis for the AChE-VP2.33 trajectory. Blue areas represent disappearing areas at the 50% of
the snapshots, red areas represent appearing areas at the 50% of the snapshots. Green loop corresponds to the side door, orange loop to the acyl-loop and the blue
residues to the back door.
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(cooperative activities) have allowed us to validate VP2.33 as
an allosteric inhibitor of site 3. These new allosteric modulators
are potentially useful pharmacological tools for study of non-
hydrolytic functions of cholinergic system.
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